Edarbi Approved for High Blood Pressure
But shouldn't be taken by pregnant women
MONDAY, Feb. 28 (HealthDay News) -- Edarbi (azilsartan medoxomil) has been approved by the U.S. Food and Drug Administration to treat adults with high blood pressure (hypertension).
Clinical trials showed Edarbi was more effective in lowering high blood pressure over 24 hours than two previously FDA-approved drugs, Diovan (valsartan) and Benicar (olmesartan), the agency said in a news release.
Edarbi helps lower blood pressure by blocking the action of the hormone angiotensin II, the FDA said. The most common adverse reaction was diarrhea, maker Takeda Pharmaceutical North America said in a statement.
Edarbi has a boxed label warning that it shouldn't be used by women who are pregnant. If a woman becomes pregnant while taking the drug, it should be discontinued as soon as possible, the FDA stressed.
Takeda is based in Deerfield, Ill.
The U.S. National Heart Lung and Blood Institute has more about high blood pressure.Scott Roberts Related Articles
- Recalled Supplements Linger on U.S. Store Shelves, Study Finds
October 22, 2014
- Some Lung Patients Buy Cigarettes Along With Meds at Pharmacies: Study
October 20, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright © 2011 HealthDay. All rights reserved.